申请人:Receptos, Inc.
公开号:US20160228450A1
公开(公告)日:2016-08-11
Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “
” represents either or both the R and S form of the compound):
where A, B, C, Y
1
, Y
2
, Z, R
1
, R
2
, R
3
, R
4
, R
5
, W
1
, n, p and q are as defined herein.
本文提供了调节胰高血糖素样肽-1(GLP-1)受体的化合物,以及它们的合成方法和治疗和/或预防使用方法。这些化合物可以作为GLP-1受体的调节剂或增强剂,单独使用或与肠促胰高血糖素肽(如GLP-1(7-36)和GLP-1(9-36))或基于肽的治疗(如艾塞那肽和利拉鲁肽)一起使用,并具有以下一般结构(其中“”代表化合物的R和S形式之一或两者均可):其中A、B、C、Y1、Y2、Z、R1、R2、R3、R4、R5、W1、n、p和q的定义如本文所述。